Landscape of Apolipoprotein (APOE) in the Emirati Population and Recommendations for a Genotyping Approach for Amyloid-Beta Monoclonal Antibodies (Aβ-mAbs) in Alzheimer’s Disease Patients
Wadha Mohammed, Mohamed Al Ameri, Sahar Al Marzooqi, Habiba Alsafar, Roland Olbrich, Mira Mousa, Dalia Barayan, Tiago Magalhaes, Javier Quilez, Judith Reche, Budour Alkaf, Ahmed Shatila, Nour al dain Marzouka, Imran Iqbal, Ayman Yousif, Azhar Rahma, Asma Al Mannaie · 2026
Read Landscape of Apolipoprotein (APOE) in the Emirati Population and Recommendations for a Genotyping Approach for Amyloid-Beta Monoclonal Antibodies (Aβ-mAbs) in Alzheimer’s Disease Patients by Wadha Mohammed, Mohamed Al Ameri, Sahar Al Marzooqi, Habiba Alsafar, Roland Olbrich, Mira Mousa, Dalia Barayan, Tiago Magalhaes, Javier Quilez, Judith Reche, Budour Alkaf, Ahmed Shatila, Nour al dain Marzouka, Imran Iqbal, Ayman Yousif, Azhar Rahma, Asma Al Mannaie (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13399946.txt.
Description
Wadha Mohammed and colleagues mapped the APOE gene landscape of the Emirati population to guide safer use of new anti-amyloid Alzheimer's drugs, in a 2026 analysis. The team combined Abu Dhabi health records of 2024 Alzheimer's diagnoses and antibody prescriptions with whole-genome data from 506,734 participants in the Emirati Genome Program, calling genotypes from the two defining variants.
In 2024, 1,285 Emiratis were diagnosed with Alzheimer's disease, and aducanumab had been prescribed to just eight patients across 2022 to 2024. In the genome cohort, the ε3/ε3 genotype dominated at 77.9 percent. The ε4 risk allele appeared in 14.7 percent of participants, and 0.9 percent carried two ε4 copies, the highest-risk group for ARIA. The protective ε2 allele was present in 7.5 percent of the population. The authors recommend building APOE results into the Emirati Genome Program's pharmacogenomic report so that antibody eligibility and risk counseling rest on local data rather than imported European frequencies.
Catalog record
| CREATOR | Wadha Mohammed, Mohamed Al Ameri, Sahar Al Marzooqi, Habiba Alsafar, Roland Olbrich, Mira Mousa, Dalia Barayan, Tiago Magalhaes, Javier Quilez, Judith Reche, Budour Alkaf, Ahmed Shatila, Nour al dain Marzouka, Imran Iqbal, Ayman Yousif, Azhar Rahma, Asma Al Mannaie |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25571 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |